Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-11-05
2004-03-16
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S461000, C514S631000, C514S634000
Reexamination Certificate
active
06706754
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates generally to a method of treating, preventing or inhibiting leishmaniasis in a subject. In particular, the invention relates to a method of treating, preventing or inhibiting leishmaniasis in a subject by the administration of at least one reversed amidine.
2. Description of the Related Art
Parasitic diseases have an overwhelming impact on public health in developing areas of the world. One such disease is leishmaniasis, a spectrum of disease in man that is life-threatening in its most severe form. Leishmaniasis is caused by several species of Leishmania. These unicellular organisms of the order Kinetoplastida are related to trypanosomes, the causative organisms of Sleeping Sickness in Africa and Chagas' disease in South America. Leishmania parasites commonly exist in two distinct forms, the motile promastigote of the insect vector and the sessile amastigote present in the mammalian host. Promastigotes are transmitted to humans by the bite of infected phlebotomine sandflies, which are found throughout the world's inter-tropical and temperate regions. Upon delivery into the mammalian host, promastigotes infect macrophages of the reticuloendothelial system and transform into amastigotes.
Three main clinical variants of this disease are known: cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis can manifest itself as a single skin ulceration at the site of the sandfly bite appearing soon after infection or month later as disseminated lesions. Mucocutaneous syndrome develops as the cutaneous form, but progresses months or years later to lesions of the mouth, nose, or pharynx. The major long-term effects of cutaneous and mucocutaneous disease are scarring. Visceral leishmaniasis has an incubation period of 3-6 months and involves the reticuloendothelial system.
Clinical manifestations include enlargement of the liver and spleen, fever, anemia, and weight loss. Symptomatic visceral disease often ends in death in the absence of treatment. In recent years, the coexistence of HIV and Leishmania species causing visceral disease has resulted in several hundreds of cases of dually infected individuals. See Berman, J. D., (1997)
Clin. Infect. Dis
. 24:684. The World Health Organization recently estimated in 2000 that leishmaniasis affects people in 88 countries, with 350 million at risk of contracting the disease and about two million new cases each year. The devastating impact of this disease is exemplified by the recent epidemic of visceral leishmaniasis in the Sudan, which claimed an estimated 100,000 lives. See Seaman, J., et al. (1996)
Int. J. Epidemiol
. 25:862. This disease is frequently a threat in military operations, as demonstrated by the outbreak of viscerotropic leishmaniasis during the Gulf War. See Magill, J., et al. (1993)
N Engl J Med
328:1383.
Unfortunately, few drugs or compounds exist which exhibit anti-leishmanial activity in vitro or in vivo. Pentavalent antimonial compounds have been the first line drugs for leishmaniasis since the 1940's, and two forms of Sb(V) are commonly used. Sodium stibogluconate (Pentostam® (Wellcome Foundation, London, England)) and meglumine antimoniate (Glucantime® (Rhone Poulenc, Paris, France)) are prescribed according to Sb(V) content and are generally considered to be equivalent in terms of efficacy and toxicity. These drugs must be given by injection over a 20-28 day course. Unfortunately, the antimonial compounds exhibit side effects such as nausea and severe toxic side effects, such as hepatitis, nephritis, and myocarditis. See Berman, J. D., (1997). Further, reports of unresponsiveness to antimony treatment are becoming more frequent. See Olliaro, P., et al. (1993)
Parasitol. Today
9:323. Moreover, there is a strong correlation between clinical resistance to Pentostam® and decreased in vitro susceptibility to this drug. See Lira, R., et al. (1999)
J. Infect. Dis
. 180:564.
Amphotericin B is also used as a treatment for visceral leishmaniasis. Past implementation of this drug was limited to toxic side reactions including fever, bone pain, and decreased renal function. Although new clinical formulations of amphotericin B in lipid complexes are less toxic than amphotericin B, these new clinical formulations are more expensive, and a major problem in treating visceral leishmaniasis in developing countries. Also, amphotericin B and amphotericin B-lipid complexes do not appear to be suitable for treating nonvisceral disease. See Berman, J. D., (1997). Oral miltefosine has shown some promise in the treatment of visceral leishmaniasis in India, however, efficacy against cutaneous disease has yet to be reported and miltefosine has not yet been approved for clinical use in any country. See Jha, T., et al. (1999)
N. Eng. J. Med
. 341:1795 and Sundar, S., et al. (2000)
Clin. Infect. Dis
. 31:1110.
Other compounds such as pentamidine and analogues thereof exhibit some anti-leishmanial activity. See U.S. Pat. No. 5,202,320; Steck, E. A., et al. (1981) Exp. Parasitol. 52(3):404-413; and Berman, J. D., et al. (1988) Rev. Infect. Dis. 10(3):560-586. Pentamidine is frequently used for the treatment of leishmaniasis and is currently being evaluated by the U.S. Army for use on troops infected with Leishmania. See Hellier, I., et al. (2000)
Dermatology
200:120 and Soto, J., et al. (1994)
Am. J. Trop. Med. Hyg
. 50:107. However, the drawbacks of the clinical use of pentamidine and pentamidine analogues are the route of administration (injection) and the toxicity of the compounds. Administration by injection increases the expense of the treatment and makes the use of the drug less practical in developing nations where cost is a major factor. The clinical side effects of pentamidine include renal and hepatic toxicity, pancreatitis, hypotension, dysglycemia, and cardiac abnormalities. See Berman, J. D., (1997) and Goa, K., et al. (1987)
Drugs
33:242.
Thus, a need exists for an anti-leishmanial agent for the treatment of leishmaniasis.
SUMMARY OF THE INVENTION
The present invention generally relates to compounds and methods for the treatment of leishmaniasis.
In some embodiments, the present invention provides a method for treating, preventing or inhibiting leishmaniasis in a subject comprising administering to the subject a therapeutically effective amount of at least one compound having the structural formula
wherein Y is a heteroatom; R
1
and R
2
are independently H or an alkyl, cycloalkyl, heterocycloalkyl, aryl, amino or heteroaryl group; and X
1
, X
2
, and X
3
are independently H or an alkyl, alkoxy, halo, amino, alkylamino, dialkylamino, acylamino, alkylthio, sulfonyl, cyano, carboxy, alkoxycarbonyl, or carbamoyl group. In preferred embodiments, Y is O or S, R
1
and R
2
are independently H, phenyl, cyclohexyl, quinolyl, pyridinyl, or methylpyridinyl, and X
1
, X
2
, and X
3
are independently H, Cl, amino, methyl, methoxy, ethoxy, or propan-2-oxy. Preferably, X
1
, X
2
, and X
3
are each independently at positions 2, 3, 5, or 6 of the phenyl rings, more preferably, X
1
and X
2
are each independently at positions 2 or 3. Preferably, the subject is mammalian, more preferably, the subject is human.
In some embodiments, the method further includes administering a supplementary active compound to the subject. The supplementary active compound may be sodium stibogluconate such as Pentostam®, meglumine antimoniate such as Glucantime®, pentamidine, amphotericin B, miltefosine, paromomycin, and the like.
In preferred embodiments, the compound is
2,5-Bis[4-(2-pyridylimino)aminophenyl]furan;
2,5-Bis[4-(benzimidoylamino)phenyl]furan;
2,5-Bis[4-(cyclohexylimino)aminophenyl]furan;
2,5-Bis[4-(acetimidoyl)aminophenyl]furan;
2,5-Bis[4-(benzimidoyl)amino-2-methylphenyl]furan;
2,5-Bis[2-methyl-4-(2-pyridylimino)aminophenyl]furan;
2,5-Bis[2-methyl-4-(2-quinolylimino)aminophenyl]furan;
2,5-Bis[2-methyl-4-(5-methyl-2-pyridylimino)aminophenyl]furan;
2,5-Bis[2-meth
Boykin David W.
Brendle James J.
Stephens Chad E.
Werbovetz Karl A.
Arwine Elizabeth
The United States of America as represented by the Secretary of
Weddington Kevin E.
LandOfFree
Reversed amidines and methods of using for treating,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reversed amidines and methods of using for treating,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reversed amidines and methods of using for treating,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3190382